Warren Whitehead
Directeur/Membre du Conseil chez APTOSE BIOSCIENCES INC.
Fortune : 1 160 $ au 30/04/2024
Profil
Warren Whitehead is an Independent Director at Aptose Biosciences, Inc. He is also a Vice President at St. Luke's Episcopal Hospital and the Chief Financial Officer at Resolution Pharmaceuticals, Inc. Currently, he is the Head of Corporate Strategy at Satellos Bioscience, Inc. In the past, he served as the Chairman of PlantForm Corp.
and as an Independent Non-Executive Director at Telesta Therapeutics, Inc. He was also the Chief Financial Officer and Director at ProMIS Neurosciences, Inc. from 2014 to 2015.
Additionally, he held the position of Chief Financial Officer at Arius Research, Inc. from 2006 to 2008 and at Labopharm, Inc. from 2000 to 2006.
He worked as a Principal at GlaxoSmithKline, Inc. and as the Chief Accountant at StageZero Life Sciences Ltd.
Mr. Whitehead has an undergraduate degree from the University of Western Ontario and undergraduate and MBA degrees from the University of Windsor.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
APTOSE BIOSCIENCES INC.
0,01% | 05/02/2024 | 1 000 ( 0,01% ) | 1 160 $ | 30/04/2024 |
SATELLOS BIOSCIENCE INC
-.--% | 01/06/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Warren Whitehead
| Sociétés | Poste | Début |
|---|---|---|
| APTOSE BIOSCIENCES INC. | Directeur/Membre du Conseil | 07/04/2011 |
| SATELLOS BIOSCIENCE INC. | Corporate Officer/Principal | 01/09/2023 |
St. Luke's Episcopal Hospital
 St. Luke's Episcopal Hospital Hospital/Nursing ManagementHealth Services St. Luke's Episcopal Hospital provides medical and healthcare services. Its services include home health care, outpatient, surgical, cancer care, pulmonary care, rehabilitation therapy, and other health care services. The company was founded in 1954 and is headquartered in Houston, TX | Corporate Officer/Principal | - |
| Resolution Pharmaceuticals, Inc. | Directeur Financier/CFO | - |
Anciens postes connus de Warren Whitehead
| Sociétés | Poste | Fin |
|---|---|---|
| TELESTA THERAPEUTICS INC | Directeur/Membre du Conseil | 01/01/2016 |
| PROMIS NEUROSCIENCES, INC. | Directeur Financier/CFO | 15/08/2015 |
Arius Research, Inc.
 Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Directeur Financier/CFO | - |
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Directeur Financier/CFO | 01/01/2006 |
Satellos Bioscience, Inc. /Old/
 Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Directeur Financier/CFO | - |
Formation de Warren Whitehead
| University of Windsor | Masters Business Admin |
| University of Western Ontario | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| STAGEZERO LIFE SCIENCES LTD. | Health Technology |
| SATELLOS BIOSCIENCE INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Health Technology |
St. Luke's Episcopal Hospital
St. Luke's Episcopal Hospital Hospital/Nursing ManagementHealth Services St. Luke's Episcopal Hospital provides medical and healthcare services. Its services include home health care, outpatient, surgical, cancer care, pulmonary care, rehabilitation therapy, and other health care services. The company was founded in 1954 and is headquartered in Houston, TX | Health Services |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
| Resolution Pharmaceuticals, Inc. | |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
PlantForm Corp.
 PlantForm Corp. Pharmaceuticals: MajorHealth Technology PlantForm Corp. engages in a biopharmaceutical company. It focuses on the development and production of ntibody and protein drugs using manufacturing platform. The firm’s vivoXPRESS technology uses genetically modified tobacco plants to produce biopharmaceuticals in fully contained greenhouse environments. The company was founded by J. Christopher Hall, Mark Goldberg, Don Stewart, and Ronald G. Hosking in 2008 and is headquartered in Toronto, Canada. | Health Technology |
Telesta Therapeutics, Inc.
 Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
